PDCD1 and hepatocellular carcinoma: In a mouse model of HCC, CTNNB1 mutation or activation of WNT-β-catenin pathway could downregulate CCL5 expression and dampen DC recruitment, leading to immune escape and resistance to anti-PD-1 therapy (128).